(RIGL) Rigel Pharmaceuticals - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US7665597024
Stock: Kinase Inhibitor, Blood Disorder, Cancer Therapy, Oral Treatment
Total Rating 62
Risk 35
Buy Signal -1.30
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 70.8% |
| Relative Tail Risk | -10.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.76 |
| Alpha | 35.20 |
| Character TTM | |
|---|---|
| Beta | 0.886 |
| Beta Downside | 0.734 |
| Drawdowns 3y | |
|---|---|
| Max DD | 60.31% |
| CAGR/Max DD | 0.46 |
Description: RIGL Rigel Pharmaceuticals December 29, 2025
Rigel Pharmaceuticals (NASDAQ:RIGL) is a biotech firm focused on oral small-molecule therapies for hematologic disorders and oncology, with commercial products - Tavalisse (Syk inhibitor for chronic immune thrombocytopenia), Rezlidhia (IDH1-mutant AML), and GAVRETO (RET-fusion NSCLC and thyroid cancer). Its pipeline includes R289 (IRAK1/4 inhibitor) and collaborations with BerGenBio, Eli Lilly, Daiichi Sankyo, and MD Anderson on Olutasidenib for IDH1-mutant cancers.
Key recent metrics: Q3 2024 net product revenue rose 38% YoY to $112 million, driven by double-digit growth in GAVRETO sales after its 2023 FDA approval; cash and equivalents stood at $310 million, giving ~2.5 years of runway at current burn. The biotech sector’s valuation is currently supported by a 7% CAGR in oncology-focused R&D spend and a favorable regulatory environment for targeted oral agents, which underpins Rigel’s growth potential.
For a deeper, data-driven assessment of Rigel’s valuation and risk profile, you may find the analyst tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 113.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.28 > 0.02 and ΔFCF/TA 20.67 > 1.0 |
| NWC/Revenue: 42.73% < 20% (prev 33.12%; Δ 9.61% < -1%) |
| CFO/TA 0.28 > 3% & CFO 68.2m > Net Income 113.3m |
| Net Debt (12.3m) to EBITDA (124.3m): 0.10 < 3 |
| Current Ratio: 2.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (19.2m) vs 12m ago 8.54% < -2% |
| Gross Margin: 93.10% > 18% (prev 0.89%; Δ 9221 % > 0.5%) |
| Asset Turnover: 147.7% > 50% (prev 113.0%; Δ 34.75% > 0%) |
| Interest Coverage Ratio: 16.09 > 6 (EBITDA TTM 124.3m / Interest Expense TTM 7.58m) |
Altman Z'' -15.00
| A: 0.50 (Total Current Assets 214.9m - Total Current Liabilities 94.4m) / Total Assets 242.5m |
| B: -5.32 (Retained Earnings -1.29b / Total Assets 242.5m) |
| C: 0.64 (EBIT TTM 121.9m / Avg Total Assets 191.0m) |
| D: -10.33 (Book Value of Equity -1.29b / Total Liabilities 124.9m) |
| Altman-Z'' Score: -20.66 = D |
Beneish M -2.75
| DSRI: 0.84 (Receivables 45.9m/30.6m, Revenue 282.1m/157.5m) |
| GMI: 0.96 (GM 93.10% / 89.43%) |
| AQI: 0.47 (AQ_t 0.11 / AQ_t-1 0.23) |
| SGI: 1.79 (Revenue 282.1m / 157.5m) |
| TATA: 0.19 (NI 113.3m - CFO 68.2m) / TA 242.5m) |
| Beneish M-Score: -2.75 (Cap -4..+1) = A |
What is the price of RIGL shares?
As of February 07, 2026, the stock is trading at USD 34.15 with a total of 353,852 shares traded.
Over the past week, the price has changed by -2.04%, over one month by -21.10%, over three months by -5.45% and over the past year by +40.02%.
Over the past week, the price has changed by -2.04%, over one month by -21.10%, over three months by -5.45% and over the past year by +40.02%.
Is RIGL a buy, sell or hold?
Rigel Pharmaceuticals has received a consensus analysts rating of 3.50.
Therefor, it is recommend to hold RIGL.
- StrongBuy: 1
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RIGL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 51.6 | 51.1% |
| Analysts Target Price | 51.6 | 51.1% |
| ValueRay Target Price | 34.5 | 1.1% |
RIGL Fundamental Data Overview February 03, 2026
P/E Trailing = 5.6317
P/E Forward = 11.0988
P/S = 2.2432
P/B = 5.3786
P/EG = -0.1
Revenue TTM = 282.1m USD
EBIT TTM = 121.9m USD
EBITDA TTM = 124.3m USD
Long Term Debt = 30.0m USD (from longTermDebt, last quarter)
Short Term Debt = 30.4m USD (from shortTermDebt, last quarter)
Debt = 60.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.3m USD (from netDebt column, last quarter)
Enterprise Value = 556.5m USD (632.8m + Debt 60.9m - CCE 137.1m)
Interest Coverage Ratio = 16.09 (Ebit TTM 121.9m / Interest Expense TTM 7.58m)
EV/FCF = 8.17x (Enterprise Value 556.5m / FCF TTM 68.1m)
FCF Yield = 12.24% (FCF TTM 68.1m / Enterprise Value 556.5m)
FCF Margin = 24.16% (FCF TTM 68.1m / Revenue TTM 282.1m)
Net Margin = 40.17% (Net Income TTM 113.3m / Revenue TTM 282.1m)
Gross Margin = 93.10% ((Revenue TTM 282.1m - Cost of Revenue TTM 19.5m) / Revenue TTM)
Gross Margin QoQ = 93.16% (prev 95.57%)
Tobins Q-Ratio = 2.29 (Enterprise Value 556.5m / Total Assets 242.5m)
Interest Expense / Debt = 3.11% (Interest Expense 1.89m / Debt 60.9m)
Taxrate = 4.80% (881.0k / 18.4m)
NOPAT = 116.1m (EBIT 121.9m * (1 - 4.80%))
Current Ratio = 2.28 (Total Current Assets 214.9m / Total Current Liabilities 94.4m)
Debt / Equity = 0.52 (Debt 60.9m / totalStockholderEquity, last quarter 117.6m)
Debt / EBITDA = 0.10 (Net Debt 12.3m / EBITDA 124.3m)
Debt / FCF = 0.18 (Net Debt 12.3m / FCF TTM 68.1m)
Total Stockholder Equity = 55.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 59.33% (Net Income 113.3m / Total Assets 242.5m)
RoE = 204.7% (Net Income TTM 113.3m / Total Stockholder Equity 55.3m)
RoCE = 142.9% (EBIT 121.9m / Capital Employed (Equity 55.3m + L.T.Debt 30.0m))
RoIC = 100.8% (NOPAT 116.1m / Invested Capital 115.1m)
WACC = 8.63% (E(632.8m)/V(693.6m) * Re(9.18%) + D(60.9m)/V(693.6m) * Rd(3.11%) * (1-Tc(0.05)))
Discount Rate = 9.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.78%
[DCF Debug] Terminal Value 67.39% ; FCFF base≈45.0m ; Y1≈29.6m ; Y5≈13.5m
Fair Price DCF = 12.40 (EV 237.4m - Net Debt 12.3m = Equity 225.0m / Shares 18.2m; r=8.63% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 78.29 | EPS CAGR: 169.6% | SUE: 1.30 | # QB: 6
Revenue Correlation: 85.02 | Revenue CAGR: 38.63% | SUE: 0.74 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.70 | Chg30d=-0.095 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=3.72 | Chg30d=-0.623 | Revisions Net=-3 | Growth EPS=-44.4% | Growth Revenue=-5.9%
P/E Forward = 11.0988
P/S = 2.2432
P/B = 5.3786
P/EG = -0.1
Revenue TTM = 282.1m USD
EBIT TTM = 121.9m USD
EBITDA TTM = 124.3m USD
Long Term Debt = 30.0m USD (from longTermDebt, last quarter)
Short Term Debt = 30.4m USD (from shortTermDebt, last quarter)
Debt = 60.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.3m USD (from netDebt column, last quarter)
Enterprise Value = 556.5m USD (632.8m + Debt 60.9m - CCE 137.1m)
Interest Coverage Ratio = 16.09 (Ebit TTM 121.9m / Interest Expense TTM 7.58m)
EV/FCF = 8.17x (Enterprise Value 556.5m / FCF TTM 68.1m)
FCF Yield = 12.24% (FCF TTM 68.1m / Enterprise Value 556.5m)
FCF Margin = 24.16% (FCF TTM 68.1m / Revenue TTM 282.1m)
Net Margin = 40.17% (Net Income TTM 113.3m / Revenue TTM 282.1m)
Gross Margin = 93.10% ((Revenue TTM 282.1m - Cost of Revenue TTM 19.5m) / Revenue TTM)
Gross Margin QoQ = 93.16% (prev 95.57%)
Tobins Q-Ratio = 2.29 (Enterprise Value 556.5m / Total Assets 242.5m)
Interest Expense / Debt = 3.11% (Interest Expense 1.89m / Debt 60.9m)
Taxrate = 4.80% (881.0k / 18.4m)
NOPAT = 116.1m (EBIT 121.9m * (1 - 4.80%))
Current Ratio = 2.28 (Total Current Assets 214.9m / Total Current Liabilities 94.4m)
Debt / Equity = 0.52 (Debt 60.9m / totalStockholderEquity, last quarter 117.6m)
Debt / EBITDA = 0.10 (Net Debt 12.3m / EBITDA 124.3m)
Debt / FCF = 0.18 (Net Debt 12.3m / FCF TTM 68.1m)
Total Stockholder Equity = 55.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 59.33% (Net Income 113.3m / Total Assets 242.5m)
RoE = 204.7% (Net Income TTM 113.3m / Total Stockholder Equity 55.3m)
RoCE = 142.9% (EBIT 121.9m / Capital Employed (Equity 55.3m + L.T.Debt 30.0m))
RoIC = 100.8% (NOPAT 116.1m / Invested Capital 115.1m)
WACC = 8.63% (E(632.8m)/V(693.6m) * Re(9.18%) + D(60.9m)/V(693.6m) * Rd(3.11%) * (1-Tc(0.05)))
Discount Rate = 9.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.78%
[DCF Debug] Terminal Value 67.39% ; FCFF base≈45.0m ; Y1≈29.6m ; Y5≈13.5m
Fair Price DCF = 12.40 (EV 237.4m - Net Debt 12.3m = Equity 225.0m / Shares 18.2m; r=8.63% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 78.29 | EPS CAGR: 169.6% | SUE: 1.30 | # QB: 6
Revenue Correlation: 85.02 | Revenue CAGR: 38.63% | SUE: 0.74 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.70 | Chg30d=-0.095 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=3.72 | Chg30d=-0.623 | Revisions Net=-3 | Growth EPS=-44.4% | Growth Revenue=-5.9%